Cellebrite DI Ltd. (NASDAQ:CLBT) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT) have earned an average recommendation of “Buy” from the seven analysts that are currently covering the company, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $17.33.

A number of equities research analysts have recently weighed in on CLBT shares. Craig Hallum lifted their price objective on Cellebrite DI from $16.00 to $20.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Deutsche Bank Aktiengesellschaft lifted their target price on Cellebrite DI from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Friday, August 16th. Bank of America increased their price target on shares of Cellebrite DI from $13.00 to $17.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Needham & Company LLC lifted their price objective on shares of Cellebrite DI from $14.00 to $17.00 and gave the company a “buy” rating in a report on Friday, August 16th. Finally, JPMorgan Chase & Co. increased their target price on shares of Cellebrite DI from $14.00 to $15.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. IGP Investments G.P.L.P LP acquired a new stake in shares of Cellebrite DI in the 4th quarter valued at $182,619,000. Clal Insurance Enterprises Holdings Ltd raised its stake in Cellebrite DI by 7.8% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 7,086,158 shares of the company’s stock valued at $56,446,000 after buying an additional 514,858 shares in the last quarter. Crosslink Capital Inc. lifted its holdings in Cellebrite DI by 1.4% during the 4th quarter. Crosslink Capital Inc. now owns 3,240,480 shares of the company’s stock worth $28,063,000 after buying an additional 44,520 shares during the last quarter. Acadian Asset Management LLC lifted its holdings in Cellebrite DI by 26.8% during the 1st quarter. Acadian Asset Management LLC now owns 2,896,497 shares of the company’s stock worth $32,062,000 after buying an additional 612,787 shares during the last quarter. Finally, Ashford Capital Management Inc. boosted its position in shares of Cellebrite DI by 23.5% during the 1st quarter. Ashford Capital Management Inc. now owns 1,841,240 shares of the company’s stock worth $20,401,000 after acquiring an additional 350,140 shares in the last quarter. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Cellebrite DI Trading Down 3.0 %

Shares of NASDAQ:CLBT opened at $16.34 on Wednesday. The business has a 50-day moving average price of $14.12 and a 200 day moving average price of $12.31. Cellebrite DI has a 12-month low of $6.36 and a 12-month high of $17.48. The company has a market capitalization of $3.36 billion, a price-to-earnings ratio of -28.17, a PEG ratio of 2.32 and a beta of 1.52.

Cellebrite DI (NASDAQ:CLBT) last released its quarterly earnings results on Thursday, August 15th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.02. Cellebrite DI had a negative net margin of 28.51% and a positive return on equity of 5,902.06%. The business had revenue of $95.70 million for the quarter, compared to the consensus estimate of $91.94 million. During the same period in the previous year, the firm earned $0.05 EPS. The business’s revenue was up 24.8% on a year-over-year basis. As a group, equities research analysts predict that Cellebrite DI will post 0.31 earnings per share for the current fiscal year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.